Standard uptake value of positron emission tomography in clinical stage i lung cancer

Clinical application and pathological correlation

Tsai Wang Huang, Chih Ming Hsieh, Hung Chang, Yeung Leung Cheng, Ching Tzao, Wen Shen Huang, Shih Chun Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: The aim of this study was to assess the standard uptake value in clinical stage I non-small cell lung cancer (NSCLC) and its correlation with pathological status and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with NSCLC between January 2002 and June 2005. Patients with clinical stage I diseases undergone a preoperative positron emission tomography-computed tomography scan followed by anatomic resection. We reviewed the clinical features of 152 patients withan average follow-up of 87 months. Results: We analysed the clinical features of 108 patients with stage I NSCLC and 44 patients with non-stage I NSCLC. There were no statistical differences in age, histological type, location or tumour differentiation between the two groups. In the Stage I group, the patients had lower maximum standard uptake value (SUVmax; 3.80± 3.17 vs 5.73± 3.65, P =0.001), lower carcinoembryonic antigen (CEA) levels (2.86± 4.80 vs 9.11± 17.21 ng/ml, P= 0.027) and smaller tumour size (2.39± 0.98 vs 3.73± 2.04 cm, P <0.001). The patients with higher SUVmax had a more advanced pathological stage, poorer tumour differentiation and larger tumour size. A higher SUVmax was an independent factor predicting an advanced pathological stage (SUVmax =3.3, odds ratio 3.246). The median survival of patients with SUVmax =3.3 and SUVmax

Original languageEnglish
Pages (from-to)868-873
Number of pages6
JournalEuropean Journal of Cardio-thoracic Surgery
Volume41
Issue number4
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Neoplasms
Carcinoembryonic Antigen
Odds Ratio
Survival

Keywords

  • Lung cancer
  • PET
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Standard uptake value of positron emission tomography in clinical stage i lung cancer : Clinical application and pathological correlation. / Huang, Tsai Wang; Hsieh, Chih Ming; Chang, Hung; Cheng, Yeung Leung; Tzao, Ching; Huang, Wen Shen; Lee, Shih Chun.

In: European Journal of Cardio-thoracic Surgery, Vol. 41, No. 4, 2012, p. 868-873.

Research output: Contribution to journalArticle

Huang, Tsai Wang ; Hsieh, Chih Ming ; Chang, Hung ; Cheng, Yeung Leung ; Tzao, Ching ; Huang, Wen Shen ; Lee, Shih Chun. / Standard uptake value of positron emission tomography in clinical stage i lung cancer : Clinical application and pathological correlation. In: European Journal of Cardio-thoracic Surgery. 2012 ; Vol. 41, No. 4. pp. 868-873.
@article{fd3fdfde30424dae90d8aafd458cc39a,
title = "Standard uptake value of positron emission tomography in clinical stage i lung cancer: Clinical application and pathological correlation",
abstract = "Objectives: The aim of this study was to assess the standard uptake value in clinical stage I non-small cell lung cancer (NSCLC) and its correlation with pathological status and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with NSCLC between January 2002 and June 2005. Patients with clinical stage I diseases undergone a preoperative positron emission tomography-computed tomography scan followed by anatomic resection. We reviewed the clinical features of 152 patients withan average follow-up of 87 months. Results: We analysed the clinical features of 108 patients with stage I NSCLC and 44 patients with non-stage I NSCLC. There were no statistical differences in age, histological type, location or tumour differentiation between the two groups. In the Stage I group, the patients had lower maximum standard uptake value (SUVmax; 3.80± 3.17 vs 5.73± 3.65, P =0.001), lower carcinoembryonic antigen (CEA) levels (2.86± 4.80 vs 9.11± 17.21 ng/ml, P= 0.027) and smaller tumour size (2.39± 0.98 vs 3.73± 2.04 cm, P <0.001). The patients with higher SUVmax had a more advanced pathological stage, poorer tumour differentiation and larger tumour size. A higher SUVmax was an independent factor predicting an advanced pathological stage (SUVmax =3.3, odds ratio 3.246). The median survival of patients with SUVmax =3.3 and SUVmax",
keywords = "Lung cancer, PET, Prognosis",
author = "Huang, {Tsai Wang} and Hsieh, {Chih Ming} and Hung Chang and Cheng, {Yeung Leung} and Ching Tzao and Huang, {Wen Shen} and Lee, {Shih Chun}",
year = "2012",
doi = "10.1093/ejcts/ezr113",
language = "English",
volume = "41",
pages = "868--873",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Standard uptake value of positron emission tomography in clinical stage i lung cancer

T2 - Clinical application and pathological correlation

AU - Huang, Tsai Wang

AU - Hsieh, Chih Ming

AU - Chang, Hung

AU - Cheng, Yeung Leung

AU - Tzao, Ching

AU - Huang, Wen Shen

AU - Lee, Shih Chun

PY - 2012

Y1 - 2012

N2 - Objectives: The aim of this study was to assess the standard uptake value in clinical stage I non-small cell lung cancer (NSCLC) and its correlation with pathological status and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with NSCLC between January 2002 and June 2005. Patients with clinical stage I diseases undergone a preoperative positron emission tomography-computed tomography scan followed by anatomic resection. We reviewed the clinical features of 152 patients withan average follow-up of 87 months. Results: We analysed the clinical features of 108 patients with stage I NSCLC and 44 patients with non-stage I NSCLC. There were no statistical differences in age, histological type, location or tumour differentiation between the two groups. In the Stage I group, the patients had lower maximum standard uptake value (SUVmax; 3.80± 3.17 vs 5.73± 3.65, P =0.001), lower carcinoembryonic antigen (CEA) levels (2.86± 4.80 vs 9.11± 17.21 ng/ml, P= 0.027) and smaller tumour size (2.39± 0.98 vs 3.73± 2.04 cm, P <0.001). The patients with higher SUVmax had a more advanced pathological stage, poorer tumour differentiation and larger tumour size. A higher SUVmax was an independent factor predicting an advanced pathological stage (SUVmax =3.3, odds ratio 3.246). The median survival of patients with SUVmax =3.3 and SUVmax

AB - Objectives: The aim of this study was to assess the standard uptake value in clinical stage I non-small cell lung cancer (NSCLC) and its correlation with pathological status and prognosis. Methods: We retrospectively reviewed 674 patients diagnosed with NSCLC between January 2002 and June 2005. Patients with clinical stage I diseases undergone a preoperative positron emission tomography-computed tomography scan followed by anatomic resection. We reviewed the clinical features of 152 patients withan average follow-up of 87 months. Results: We analysed the clinical features of 108 patients with stage I NSCLC and 44 patients with non-stage I NSCLC. There were no statistical differences in age, histological type, location or tumour differentiation between the two groups. In the Stage I group, the patients had lower maximum standard uptake value (SUVmax; 3.80± 3.17 vs 5.73± 3.65, P =0.001), lower carcinoembryonic antigen (CEA) levels (2.86± 4.80 vs 9.11± 17.21 ng/ml, P= 0.027) and smaller tumour size (2.39± 0.98 vs 3.73± 2.04 cm, P <0.001). The patients with higher SUVmax had a more advanced pathological stage, poorer tumour differentiation and larger tumour size. A higher SUVmax was an independent factor predicting an advanced pathological stage (SUVmax =3.3, odds ratio 3.246). The median survival of patients with SUVmax =3.3 and SUVmax

KW - Lung cancer

KW - PET

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84862506399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862506399&partnerID=8YFLogxK

U2 - 10.1093/ejcts/ezr113

DO - 10.1093/ejcts/ezr113

M3 - Article

VL - 41

SP - 868

EP - 873

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 4

ER -